Physician profile
Sidney Chadwell
NPI 1902827801
$10,165.22
in general payments reported to CMS, 2019-2025
50 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,990 · 2020: $1,348 · 2021: $2,195 · 2022: $1,425 · 2023: $1,280 · 2024: $1,023 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.03 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,710.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $850.76 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $821.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $798.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $700.41 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $597.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $576.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $482.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $435.89 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $385.15 | 2019-2023 | Spravato, Xarelto |
| Mylan Specialty L.P. | $335.07 | 2020-2024 | Yupelri |
| Astellas Pharma US INC | $306.86 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $207.88 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.69 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $162.34 | 2023-2024 | Quviviq |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Chadwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.